Loading...
A recently published study compared oral rosiglitazone (Avandia) and a single daily injection of insulin glargine (Lantus) as add-on therapy for 217 patients with type 2 diabetes whose glycemic control was inadequate with metformin and sulfonylurea (Journal Watch Mar 17 2006). The study, funded by the maker of insulin glargine, found similar glycemic control in the insulin and rosiglitazone groups at 24 weeks. An additional outcome of interest, quality of life, is addressed in a new report from that study.
Both groups improved in most quality-of-life indicators at 24 weeks, as assessed by standardized questionnaires. However, improvements in a total symptom score and a total symptom distress score were significantly greater in the insulin gr…